お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:KOLの考察:黒色腫 (メラノーマ) 2020年
市場調査レポート
商品コード
995057

KOLの考察:黒色腫 (メラノーマ) 2020年

KOL Insight: Melanoma 2020

出版日: | 発行: FirstWord | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.15円
KOLの考察:黒色腫 (メラノーマ) 2020年
出版日: 2020年10月13日
発行: FirstWord
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、黒色腫 (メラノーマ) の市販薬およびパイプライン治療薬の見通しについて、米国および欧州のKOLによる評価を提供しています。

目次

エグゼクティブサマリー

治療アルゴリズム

調査目的

市販の治療薬

  • 概要
  • 免疫療法
    • 重要考察のサマリー
    • Yervoy (ipilimumab; Bristol Myers Squibb)
    • Opdivo (nivolumab; Bristol Myers Squibb/Ono Pharmaceutical)
    • Keytruda (pembrolizumab; Merck & Co.)

BRAF / MEK阻害剤

  • 概要
    • 重要考察のサマリー
  • 市販のBRAF / MEK薬
    • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis) Zelboraf/Cotellic (vemurafenib/cobimetinib; Roche) Braftovi/Mektovi (encorafenib/binimetinib; Array Biopharma)

腫瘍溶解性ウイルス/免疫賦活剤

  • 概要
    • Imlygic (talimogene laherparepvec; Amgen)

パイプライン治療薬

  • 概要

CTLA4 / PD-1 / PDL-1 / LAG-3阻害剤

  • 概要
    • 重要考察のサマリー
    • Key insights summary IBI310 (ipilimumab biosimilar; Innovent Biologics) Relatlimab (Bristol Myers Squibb/Ono Pharmaceuticals) Spartalizumab (PDR001; Novartis) Tyvyt (sintilimab; Innovent Biologics/Lilly

トール様受容体9(TLR9)アゴニスト

  • 概要
    • 重要考察のサマリー
    • Tilsotolimod(Idera Pharmaceuticals)

VEGFR / FGFR / PDGFR / RTK阻害剤

  • 概要
    • 重要考察のサマリー
    • Lenvima (lenvatinib; Eisai/Merck & Co.)

組換え免疫刺激剤

  • 概要
    • 重要考察のサマリー
    • Bempegaldesleukin (Nektar/BMS)
    • Seviprotimut-L (POL 103A; Polynoma)

初期段階のパイプライン薬

  • 概要
    • 重要考察のサマリー
    • ATG-019 (KPT-9274; Karyopharm Therapeutics)
    • BI-1206 (BioInvent International)
    • BNT111 (BioNTech)
    • Ceralasertib (AstraZeneca)
    • Inlyta (axitinib; Pfizer)
    • IO102 (IO Biotech)
    • LN-144 (lifileucel; Iovance Biotherapeutics)
    • Tebentafusp (Immunocore)

付録

ニュース

目次

Must-Know Insights From The World's Foremost Thought-Leaders

Answer critical business questions with deep intelligence from those already in-the-know

Why do KOLs foresee an expansion of Merck's anti-PD-1 therapy Keytruda in the adjuvant setting? Could Eli Lilly/Innovent Biologics' sintilimab/ipilimumab biosimilar combination threaten BMS' Opdivo/Yervoy domination of advanced melanoma treatment? <>And why do KOLs believe Iovance Biotherapeutics' pipeline lifileucel has the potential to change practice for patients' refractory to multiple-lines of therapy? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.

Key questions answered:

  • Why do oncologists suggest the anti-PD1/CTLA4 blockade could be practice changing in the neoadjuvant setting?
  • Why are experts underwhelmed with Roche's triple combination of Tecentriq with Cotellic/Zelboraf?
  • Why do KOLs believe Nektar/BMS' late stage bempegaldesleukin/nivolumab combination could be a potential competitor to Opdivo/Yervoy?
  • How and where do oncologists see potential value for Idera's PIII tilsotolimod/Yervoy combination?

Examples of Therapies Covered:

  • Yervoy
  • Keytruda
  • Tafinlar/Mekinist
  • Relatlimab
  • Tilsotolimod
  • Opdivo
  • IBI310
  • Zelboraf/Cotellic
  • Spartalizumab
  • Tyvyt

Partial List of Participating KOLs:

  • Oncology Specialist, MedStar Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC.
  • Professor of Medicine (Hematology/Oncology), Roswell Park Cancer Institute, 915 CSC Building, Elm and Carlton Streets, Buffalo, NY.
  • Oncology Specialist, Professor, Moffitt Cancer Center and University of South Florida Morsani College of Medicine, Tampa, FL.
  • Professor & Chief Scientific Officer, Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS Utrecht, Netherlands.
  • Professor of Medicine, Head of the Dermatology Unit at the Gustave Roussy Cancer Centre, Villejuif-Paris, France.
  • Professor of Medicine, University of Zurich, Vice-Chairman, Department of Dermatology, University Hospital of Zürich. Switzerland.

Table of Contents

Executive summary

Treatment algorithm

Research objectives

Marketed therapies

  • Overview
  • Immunotherapies
    • Key insights summary
    • Yervoy (ipilimumab; Bristol Myers Squibb)
    • Opdivo (nivolumab; Bristol Myers Squibb/Ono Pharmaceutical)
    • Keytruda (pembrolizumab; Merck & Co.)

BRAF/MEK inhibitors

  • Overview
    • Key insights summary
  • Marketed BRAF/MEK drugs
    • Tafinlar/Mekinist (dabrafenib/trametinib; Novartis)
    • Zelboraf/Cotellic (vemurafenib/cobimetinib; Roche)
    • Braftovi/Mektovi (encorafenib/binimetinib; Array Biopharma)

Oncolytic viruses/immunostimulants

  • Overview
    • Imlygic (talimogene laherparepvec; Amgen)

Pipeline therapies

  • Overview

CTLA4/PD-1/PDL-1/LAG-3 inhibitors

  • Overview
    • Key insights summary
    • IBI310 (ipilimumab biosimilar; Innovent Biologics)
    • Relatlimab (Bristol Myers Squibb/Ono Pharmaceuticals)
    • Spartalizumab (PDR001; Novartis)
    • Tyvyt (sintilimab; Innovent Biologics/Lilly

Toll-like receptor 9 (TLR9) agonists

  • Overview
    • Key insights summary
    • Tilsotolimod (Idera Pharmaceuticals)

VEGFR/FGFR/PDGFR/RTK inhibitors

  • Overview
    • Key insights summary
    • Lenvima (lenvatinib; Eisai/Merck & Co.)

Recombinant immunostimulants

  • Overview
    • Key insights summary
    • Bempegaldesleukin (Nektar/BMS)
    • Seviprotimut-L (POL 103A; Polynoma)

Early-stage pipeline drugs

  • Overview
    • Key insights summary
    • ATG-019 (KPT-9274; Karyopharm Therapeutics)
    • BI-1206 (BioInvent International)
    • BNT111 (BioNTech)
    • Ceralasertib (AstraZeneca)
    • Inlyta (axitinib; Pfizer)
    • IO102 (IO Biotech)
    • LN-144 (lifileucel; Iovance Biotherapeutics)
    • Tebentafusp (Immunocore)

Appendix

  • KOL details
    • KOLs from North America
    • KOLs from Europe

News

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.